Zobrazeno 1 - 10
of 280
pro vyhledávání: '"Inhibidors"'
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 38, Iss 1 (2023)
In the present work, we studied the inhibitory and kinetic implications of classical PTP1B inhibitors (chlorogenic acid, ursolic acid, suramin) using three enzyme constructs (hPTP1B1-285, hPTP1B1-321, and hPTP1B1-400). The results indicate that the u
Externí odkaz:
https://doaj.org/article/d9b22f6f1731457b9a605dbd036f1d1b
Autor:
Ruben A. Mesa, Stacie Hudgens, Lysbeth Floden, Claire N. Harrison, Jeanne Palmer, Vikas Gupta, Donal P. McLornan, Mary F. McMullin, Jean‐Jaques Kiladjian, Lynda Foltz, Uwe Platzbecker, M. Laura Fox, Adam J. Mead, David M. Ross, Stephen T. Oh, Andrew Perkins, Michael F. Leahy, Samineh Deheshi, Rafe Donahue, Barbara J. Klencke, Srdan Verstovsek
Publikováno v:
Mesa, R A, Hudgens, S, Floden, L, Harrison, C N, Palmer, J, Gupta, V, McLornan, D P, McMullin, M F, Kiladjian, J-J, Foltz, L, Platzbecker, U, Fox, M L, Mead, A J, Ross, D M, Oh, S T, Perkins, A, Leahy, M F, Deheshi, S, Donahue, R, Klencke, B J & Verstovsek, S 2023, ' Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies ', Cancer Medicine . https://doi.org/10.1002/cam4.5799
Scientia
Scientia
Momelotinib; Myelofibrosis; Patient-reported outcomes Momelotinib; Mielofibrosi; Resultats informats pel pacient Momelotinib; Mielofibrosis; Resultados informados por el paciente Background Myelofibrosis (MF)-associated constitutional symptoms can se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcfbb9cc40d930868fce1d2a253b5f47
https://doi.org/10.1002/cam4.5799
https://doi.org/10.1002/cam4.5799
Autor:
Annachiara Gandini, Ana Elisa Gonçalves, Silvia Strocchi, Claudia Albertini, Jana Janočková, Anna Tramarin, Daniela Grifoni, Eleonora Poeta, Ondrej Soukup, Diego Muñoz-Torrero, Barbara Monti, Raimon Sabaté, Manuela Bartolini, Giuseppe Legname, Maria Laura Bolognesi
Publikováno v:
ACS Chemical Neuroscience. 13:3314-3329
Alzheimer's disease (AD), the most common type of dementia, currently represents an extremely challenging and unmet medical need worldwide. Amyloid-β (Aβ) and Tau proteins are prototypical AD hallmarks, as well as validated drug targets. Accumulati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::120f6def0a91bcbe6be2b2a3c0aece78
https://doi.org/10.1021/acschemneuro.2c00357
https://doi.org/10.1021/acschemneuro.2c00357
Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe
Autor:
Rossella Elisei, Enrique Grande, Michael C. Kreissl, Sophie Leboulleux, Tarun Puri, Nicolas Fasnacht, Jaume Capdevila
Publikováno v:
Scientia
Medullary thyroid cancer; Tyrosine kinase inhibitor Cáncer medular de tiroides; Inhibidor de la tirosina cinasa Càncer medul·lar de tiroide; Inhibidor de la tirosina cinasa The incidence of thyroid cancer is increasing worldwide with the disease b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e8c6798b2cf549fa1760d5c75162a4c
https://hdl.handle.net/11351/9609
https://hdl.handle.net/11351/9609
Autor:
Alessio Fiascarelli, Giuseppe Merlino, Stefania Capano, Simone Talucci, Diego Bisignano, Alessandro Bressan, Daniela Bellarosa, Corrado Carrisi, Alessandro Paoli, Mario Bigioni, Patrizia Tunici, Clelia Irrissuto, Massimiliano Salerno, Joaquin Arribas, Elisa de Stanchina, Maurizio Scaltriti, Monica Binaschi
Publikováno v:
Scientia
Purpose Dysregulation of the PI3K pathway is one of the most common events in breast cancer. Here we investigate the activity of the PI3K inhibitor MEN1611 at both molecular and phenotypic levels by dissecting and comparing its profile and efficacy i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::106976cb77db0f365733f8e2231bb9ed
https://hdl.handle.net/11351/9983
https://hdl.handle.net/11351/9983
Autor:
Michael J. Hanley, Manolo D'Arcangelo, Enriqueta Felip, Pilar Garrido, Jiaxi Zhu, Meng Ye, Florin Vranceanu, Neeraj Gupta
Publikováno v:
Scientia
Anaplastic lymphoma kinase; Brigatinib; Drug-drug interaction Quinasa del linfoma anaplásico; Brigatinib; Interacción fármaco-fármaco Quinasa del limfoma anaplàstic; Brigatinib; Interacció medicament-medicament Brigatinib is a next-generation a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4f10869bd60746c4f94734d9ca837db
https://hdl.handle.net/11351/9443
https://hdl.handle.net/11351/9443
Autor:
García Martínez, Rafael, Sanz Gea, Clara, Martin Riera, Victor, Guerra-Ruiz, Armando, Paciucci Barzanti, Rosanna, Ferrer Costa, Roser, Ramírez Serra, Clara
Publikováno v:
Scientia
Dasatinib; Pleural effusion chylothorax Dasatinib; Derrame pleural quilotórax Dasatinib; Vessament pleural quilotòrax Dasatinib is a tyrosine kinase inhibitor drug used for chronic myeloid leukaemia (CML) treatment. Chylothorax has been rarely repo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3991::6195967669a2e1a957b9e627177d10e5
https://hdl.handle.net/11351/9488
https://hdl.handle.net/11351/9488
Autor:
Silvana Mouron, Maria J Bueno, Manuel Muñoz, Raul Torres, Sandra Rodríguez, Juan V Apala, Jorge Silva, Rodrigo Sánchez-Bayona, Luis Manso, Juan Guerra, Laura Rodriguez-Lajusticia, Diego Malon, Marcos Malumbres, Miguel Quintela-Fandino
Publikováno v:
Scientia
Biomarker; Hormone receptor-positive; Breast cancer Biomarcador; Cáncer de mama; Receptor hormonal positivo Biomarcador; Càncer de mama; Receptor hormonal positiu CDK4/6 inhibitors benefit a minority of patients who receive them in the breast cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51f3d09b26dbbfec698c27a90cca9464
https://hdl.handle.net/11351/9407
https://hdl.handle.net/11351/9407
Autor:
Albert Ariza-Solé, Gemma Mateus-Porta, Francesc Formiga, Sergio Garcia-Blas, Clara Bonanad, Iván Núñez-Gil, Carlos Vergara-Uzcategui, Pablo Díez-Villanueva, Jordi Bañeras, Clara Badia-Molins, Jaime Aboal, José Carreras-Mora, Ana Gabaldón-Pérez, José Antonio Parada-Barcia, Manuel Martínez-Sellés, Josep Comín-Colet, Sergio Raposeiras-Roubin
Publikováno v:
Scientia
Background Current guidelines recommend extending the use of dual antiplatelet therapy (DAPT) beyond 1 year in patients with an acute coronary syndrome (ACS) and a high risk of ischaemia and low risk of bleeding. No data exist about the implementatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a84693290112b765fba90f0f62195992
http://hdl.handle.net/2445/196043
http://hdl.handle.net/2445/196043
Publikováno v:
Scientia
JAK inhibitors; Oral therapies; Small molecules Inhibidors de JAK; Teràpies orals; Molècules petites Inhibidores de JAK; Terapias orales; Moléculas pequeñas Inflammatory bowel disease (IBD) is a chronic immune-mediated condition of the gastrointe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e74e2328854f4736f2681aff4e531147
https://hdl.handle.net/11351/9272
https://hdl.handle.net/11351/9272